Skip to main content

Anticytokine Autoantibodies in Rheumatic Diseases

Friday, November 08, 2013 — Poster Session III

10:00 a.m. – 12:00 p.m.

FAES Academic Center (Upper-Level Terrace)




  • L.B. Rosen
  • I.P. Tatouli
  • H.M. Moutsopopoulos
  • S. Hasni
  • R.M. Siegel
  • S.M. Holland
  • S.K. Browne


Anticytokine-autoantibodies (AC-aabs) have been shown in rheumatic conditions, although their significance not well characterized. We aim to evaluate spectrum of AC-aabs in SLE, RA and Sjogren’s Disease. Bio-Plex Pro Magnetic beads were coupled with commercially available cytokines. Sera from patients (N=399) and normals (N=179) were screened for AC-aabs against 25 different cytokine-conjugated beads, in multi-plex. Normal range for each AC-aab defined by the 99th percentile for healthy controls, outlying classified positive. Fifty patients with SLE, 21 Sjogren’s and 42 RA were positive. Anti-TNFα and anti-TNFβ antibodies were seen in 40 and 12 patients, majority of whom had RA and could be due to therapy with biologic monoclonals. IFN Type I, II and III aabs were identified more in SLE patients. We found antibodies to IL-4 and IP-10 in 9 and 12 patients respectively. Aabs against type I and type II IFN; TNFα, TNFβ; IL-1α, IL-6, IL-10, IL-12 have been described in the rheumatology literature and were seen here. Aabs against GM-CSF, M-CSF, IL-7, IL-17, and IL-22 have been reported in other diseases, aabs to type III IFNs, IL-4, IP-10, are newly identified. We will complete AC-aabs testing of remaining samples and evaluate their biological activity in vitro.

back to top